Efficacy of Bifidobacterium Longum 35624 on the Quality of Life of IBS Patients With Different Symptom Severity
NCT ID: NCT04662502
Last Updated: 2021-03-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
220 participants
OBSERVATIONAL
2018-11-22
2020-06-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome
NCT00135031
Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome
NCT02565550
Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome
NCT02213172
Microbiota, Metabolome and Nutrition: an 'Artificially Intelligent' Way to Personalized Nutrition
NCT06420843
The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients
NCT02254629
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bifidobacterium longum 35624
Bifidobacterium longum 35624, 1 x 10\^9 CFU/capsule, 1 capsule/day over 1 month
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gastroenterology consultation for an Irritable Bowel Syndrome according to Rome IV criteria
* Having received a first prescription of Bifidobacterium longum 35624 during the consultation (independently of participation in the observatory)
* Informed and having declared his/her non-opposition to the study.
Exclusion Criteria
* Having already taken Bifidobacterium longum 35624
* Having received probiotics or antibiotics within 2 weeks previous
* Having started within the last 7 days a treatment that can interfere with the investigator's evaluation of the investigational product under investigation
* Participant in another trial
* Pregnant or breastfeeding women
* Being under guardianship or curator.
* Not having a good enough command of reading and comprehension of the French language to correctly complete the questionnaires and the notebook
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biocodex
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gyasi K Johnson, PhD
Role: STUDY_DIRECTOR
Biocodex
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Avicenne
Bobigny, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Floravie
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.